Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;85(1):51-6.
doi: 10.1002/ajh.21580.

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival

Xuesong Han  1 , Tongzhang Zheng, Francine M Foss, Qing Lan, Theodore R Holford, Nathaniel Rothman, Shuangge Ma, Yawei Zhang
Affiliations

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival

Xuesong Han et al. Am J Hematol. 2010 Jan.

Abstract

Metabolic pathway enzymes, such as Cytochrome P450 (CYP), glutathione S-transferase (GST), and N-acetyltransferases (NAT) are involved in activation and detoxification of environmental carcinogens as well as drug metabolism. We hypothesized that the genetic variations in such metabolic pathways may affect NHL prognosis and survival. Follow-up information of 496 female NHL incident cases diagnosed during 1996-2000 in Connecticut were abstracted from the Connecticut Tumor Registry in 2008; survival analyses were conducted by comparing the Kaplan-Meier curves, and hazard ratios (HR) were computed from the Cox Proportional Hazard models adjusting for demographic and tumor characteristics which were suggested by previous studies to be determinants of NHL survival. We identified six SNPs from four metabolism genes (CYP2E1, GSTP1, GSTT1, and NAT1) that were associated with NHL survival. Specifically, polymorphisms in GSTT1 were associated with follicular lymphoma survival; and polymorphisms in CYP2E1, GSTP1, and NAT1 were associated with survival of chronic lymphocytic leukemia/small lymphocytic lymphoma. Our study suggests that genetic polymorphisms in metabolic pathways may help improve the prediction of NHL survival and prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier overall survival curves by the number of deleterious genotypes for NHL cases, Connecticut, 1995-2001.
Figure 2
Figure 2
Kaplan-Meier disease-free survival curves by the number of deleterious genotypes for NHL cases, Connecticut, 1995-2001.
See this image and copyright information in PMC

References

    1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK, editors. National Cancer Institute; Bethesda, MD: SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276. - PMC - PubMed
    1. Clarke C, O'Malley C. Chapter 28 Non-Hodgkin lymphoma. In: Ries LAG, Yong JL, Keel GE, Eisner MP, Lin YD, et al., editors. Cancer survival among adults: US SEER Program, 1988-2001, patient and tumor characteristics. National Cancer Institutes, SEER Program, NIH; Bethsda, MD: 2007. pp. 235–242.
    1. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control. 2008;19:841–858. - PubMed
    1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994. - PubMed

Publication types

MeSH terms